Product logins

Find logins to all Clarivate products below.


Sunita Nair

Senior Director, Systematic Literature Reviews and Meta-analysis

Sunita Nair is a Practice Head at Clarivate, leading our Systematic Literature Reviews and Meta- analysis Centre of Excellence. Sunita is a business leader with 25 years experience and provides leadership to our highly skilled team of systematic reviewers and meta-analysis experts. She has supported several US FDA and HTA submissions. She has formerly worked in tertiary hospitals and multinational pharmaceutical companies (Sanofi, Novartis) in India. She has vast experience in establishing businesses, and managing teams providing services in HEOR, medical writing and clinical development. Her core areas of interest include cardiovascular research, HEOR, knowledge management, market access, market research, medical communications, molecular diagnostics, and scientific writing.​

Sunita is a regular speaker at scientific conferences, on the review panel of several journals, and a National Executive Committee member of the ISPOR India chapter.​

Sunita has a PhD in Applied Biology (Molecular Biology) and a master’s degree in Microbiology from the University of Mumbai, and a Post-Graduate Diploma in Global Health Policy from the London School of Hygiene and Tropical Medicine. She is also trained in Knowledge Management, carried out at the Indian Institute of Management.​


arrow_forward
Get in touch with Sunita

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全